Charlotte McKee

CIK: 0002046433

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SION

Sionna Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

SION
Sionna Therapeutics, Inc.
Sep 17, 2026
Award(A)
Direct
50K shares-
SION
Sionna Therapeutics, Inc.
Sep 17, 2026
Award(A)
Direct
50K shares-
SION
Sionna Therapeutics, Inc.
Sep 17, 2026
Disposition(D)
Non-Qualified Stock Option (right to buy)
Direct
155.7K shares-
SION
Sionna Therapeutics, Inc.
Jan 2, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
155.7K shares-
SION
Sionna Therapeutics, Inc.
Feb 6, 2025
Award(A)
Stock Option (Right to Buy)
Direct
148.5K shares-

		Type	Shares	Price		Ownership
Sep 17, 2026	SION Sionna Therapeutics, Inc.	Award(A)	50,000	-	$0	Direct
Sep 17, 2026	SION Sionna Therapeutics, Inc.	Award(A)	50,000	-	$0	Direct
Sep 17, 2026	SION Sionna Therapeutics, Inc.	Disposition(D) Non-Qualified Stock Option (right to buy)	155,700	-	-	Direct
Jan 2, 2026	SION Sionna Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	155,700	-	-	Direct
Feb 6, 2025	SION Sionna Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	148,536	-	-	Direct

1-5 of 5 transactions

About McKee Charlotte

McKee Charlotte (SEC CIK 0002046433) files insider reports with the SEC as CMO and Head of R&D of Sionna Therapeutics, Inc. (SION).

Signal8 holds 4 ownership filings by McKee Charlotte (1 Form 3, 3 Form 4), filed between Feb 6, 2025 and Sep 18, 2026. Those filings report 5 transactions, from Feb 6, 2025 to Sep 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on McKee Charlotte's filings is in WALTHAM, MA.

Recent filings by McKee Charlotte

Sep 17, 2026: Grants or awards of SION shares (2 lines, Form 4, code A).
Sep 17, 2026: Disposition to issuer transaction of SION derivative securities (Form 4, code D).
Jan 2, 2026: Grant or award of SION derivative securities (Form 4, code A).
Feb 6, 2025: Grant or award of SION derivative securities (Form 4, code A).

Other insiders filing for Sionna Therapeutics, Inc. (SION)

RA CAPITAL MANAGEMENT, L.P., Director
Ridloff Elena, CFO and CBO
Fitzpatrick Jennifer, CLO and Head of Program Mgmt.
Cloonan Michael, President & CEO
Thompson Peter A., Director
ORBIMED ADVISORS LLC, Director

How to read Form 4 transaction codes